Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal (groups a, c, y, and w-135) oligosaccharide diphtheria crm197 conjugate vaccine
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A quadrivalent *conjugate vaccine* used for active immunization to prevent invasive disease caused by *Neisseria meningitidis* serogroups A, C, Y, and W-135. The vaccine contains capsular oligosaccharides from each serogroup, individually conjugated to a non-toxic diphtheria toxin variant (CRM197) or tetanus toxoid carrier protein, enhancing immunogenicity by promoting a T-cell–dependent immune response. It is indicated for individuals from 2 months up to 55 years of age and is not effective against serogroup B. Major clinical uses are the prevention of meningococcal meningitis, meningococcemia, and related forms of invasive disease[2][3][5][4].
- Brand names
- MenveoMenactraMenQuadfi
- Other names
- meningococcal conjugate vaccine (serogroups a, c, y, w-135)meningococcal (groups a, c, y and w-135) oligosaccharide diphtheria crm197 conjugate vaccinemenacwy vaccinemenacwy-d
02
Targets
Neuraminidase
Beyond the preview
Go deeper on meningococcal (groups a, c, y, and w-135) oligosaccharide diphtheria crm197 conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal (groups a, c, y, and w-135) oligosaccharide diphtheria crm197 conjugate vaccine.